Related Experiment Videos
Acute renal dysfunction associated with selective COX-2 inhibitor therapy
D Papaioannides1, C Bouropoulos, D Sinapides
1Department of Medicine and Urology, Arta General Hospital, Greece.
International Urology and Nephrology
|November 28, 2002
Summary
Selective COX-2 inhibitors reduce gastrointestinal issues but can cause kidney damage. This case highlights reversible acute renal failure from rofecoxib in an elderly patient, emphasizing cautious use in those with NSAID-related risks.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Selective cyclooxygenase-2 (COX-2) inhibitors offer reduced gastrointestinal (GI) adverse effects compared to traditional nonselective nonsteroidal anti-inflammatory drugs (NSAIDs).
- The potential for nephrotoxicity with selective COX-2 inhibitors remains less understood.
- Elderly patients and those with pre-existing risk factors are particularly vulnerable to NSAID-induced kidney injury.
Observation:
- A case study involving an elderly patient treated with rofecoxib, a selective COX-2 inhibitor.
- The patient presented with several risk factors typically associated with traditional NSAID-related nephrotoxicity.
- Acute renal failure was observed during the course of rofecoxib treatment.
Findings:
- The patient experienced reversible acute renal failure attributed to rofecoxib therapy.
- This suggests that selective COX-2 inhibitors, despite their GI safety profile, can pose a risk of kidney damage.
- Prostaglandin-dependent renal function is a key factor in NSAID-induced nephrotoxicity.
Implications:
- Therapy with selective COX-2 inhibitors requires a cautious approach, particularly in patients with risk factors for NSAID-related nephrotoxicity.
- Monitoring renal function is crucial for patients receiving selective COX-2 inhibitors, especially those with predisposing conditions.
- Further research is needed to fully elucidate the nephrotoxic potential of selective COX-2 inhibitors across diverse patient populations.